#	Pagina
attuale pagina	/open-fp7/projects/101809/index.html

OCTIPS

Ovarian Cancer Therapy – Innovative Models Prolong Survival

Coordinatore	MEDIZINISCHE UNIVERSITAET WIEN Organization address address: SPITALGASSE 23 city: WIEN postcode: 1090 contact info Titolo: Prof. Nome: Dan Cognome: Cacsire Casstillo-Tong Email: send email Telefono: +43 1 404007827 Fax: +43 1 404007832
Nazionalità Coordinatore	Austria [AT]
Sito del progetto	http://www.octips.eu/
Totale costo	3˙964˙946 €
EC contributo	2˙999˙302 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2011-two-stage
Funding Scheme	CP-FP
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-01-01 - 2015-12-31

Partecipanti

#	participant	country	role	EC contrib. [€]
1	MEDIZINISCHE UNIVERSITAET WIEN Organization address address: SPITALGASSE 23 city: WIEN postcode: 1090 contact info Titolo: Prof. Nome: Dan Cognome: Cacsire Casstillo-Tong Email: send email Telefono: +43 1 404007827 Fax: +43 1 404007832	AT (WIEN)	coordinator	533˙492.25
2	KATHOLIEKE UNIVERSITEIT LEUVEN Organization address address: Oude Markt 13 city: LEUVEN postcode: 3000 contact info Titolo: Ms. Nome: Tine Cognome: Heylen Email: send email Telefono: +32 16 326520 Fax: +32 16 326515	BE (LEUVEN)	participant	433˙000.00
3	ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM Organization address address: 's Gravendijkwal 230 city: ROTTERDAM postcode: 3015CE contact info Titolo: Mr. Nome: Arjan P Cognome: Bandel Email: send email Telefono: 31107035100 Fax: 31107034803	NL (ROTTERDAM)	participant	334˙561.38
4	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD city: LONDON postcode: SW7 2AZ contact info Titolo: Ms. Nome: Tatjana Cognome: Palalic Email: send email Telefono: +22 207 594 3866 Fax: +44 207 594 3868	UK (LONDON)	participant	324˙045.40
5	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) Organization address address: 101 Rue de Tolbiac city: PARIS postcode: 75654 contact info Titolo: Mr. Nome: Vincent Cognome: Boyer Email: send email Telefono: +33 467 637025	FR (PARIS)	participant	291˙012.00
6	THE UNIVERSITY OF EDINBURGH Organization address address: OLD COLLEGE, SOUTH BRIDGE city: EDINBURGH postcode: EH8 9YL contact info Titolo: Ms. Nome: Valerie Cognome: Renton Email: send email Telefono: +44 131 2429265 Fax: +44 131 2427778	UK (EDINBURGH)	participant	285˙752.00
7	CHARITE - UNIVERSITAETSMEDIZIN BERLIN Organization address address: Chariteplatz 1 city: BERLIN postcode: 10117 contact info Titolo: Ms. Nome: Eveline Cognome: Fräßdorf Email: send email Telefono: +49 30 450576024 Fax: +49 30 450576954	DE (BERLIN)	participant	241˙368.00
8	EMERGENTEC BIODEVELOPMENT GMBH Organization address address: GERSTHOFER STRASSE 29-31 city: VIENNA postcode: 1180 contact info Titolo: Dr. Nome: Bernd Cognome: Mayer Email: send email Telefono: +43 699 11349173 Fax: +43 1 4034966 19	AT (VIENNA)	participant	230˙986.00
9	INNOVO MIMETICS LIMITED Organization address address: PALMACH SUITE 2 68 city: JERUSALEM postcode: 92587 contact info Titolo: Mr. Nome: Jonathan Cognome: Goldstein Email: send email Telefono: +972 52 8445000 Fax: +972 2 5632716	IL (JERUSALEM)	participant	149˙360.00
10	CYCLACEL LIMITED Organization address address: JAMES LINDSAY PLACE UNIT 1 city: DUNDEE postcode: DD1 5JJ contact info Titolo: Dr. Nome: David Cognome: Blake Email: send email Telefono: +44 1382 206062 Fax: +44 1382 206067	UK (DUNDEE)	participant	115˙425.00
11	ALCEDIS GMBH Organization address address: WINCHESTERSTRASSE 2 city: GIESSEN postcode: 35394 contact info Titolo: Dr. Nome: Elke Cognome: Heidrich-Lorsbach Email: send email Telefono: 49641944360 Fax: 496419000000	DE (GIESSEN)	participant	60˙300.00

Mappa

Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

front prolong responsible cancer hgsoc chemotherapy innovative line first relapse pathways relapsed strategies octips bedside ultimately ovarian survival patients model molecules eoc tumour patient validate population cell treatment

Obiettivo del progetto (Objective)

'About 75% of advanced epithelial ovarian cancer (EOC) patients respond to first-line surgery and chemotherapy but most relapse and ultimately acquire platinum resistance which soon leads to death. Relapsed high grade serous ovarian cancer (HGSOC) is the single main cause of EOC-related morbidity and mortality (despite the fact that HGSOC is highly chemosensitive). We hypothesize that the primary tumour includes a small population of resistant cells that are ultimately responsible for relapse and that by targeting this population front-line we may prolong disease-free survival or even achieve cure. OCTIPS will use unique retrospective and novel prospective paired tumour samples collected at the time of diagnosis and relapse to identify and validate molecules and pathways responsible for relapse. This identification will employ cutting edge high throughput multiplatform analyses such as next generation sequencing, mRNA and miRNA expression arrays and SNP array. Known and newly defined molecules or pathways will be evaluated in innovative integrated cancer model systems, utilising cell lines and avian egg and murine xenografts. New therapies to target these molecules and pathways will be developed and validated in these model systems. In order to translate these findings into patient benefit, agents that target the relapsing cell population will be tested for tolerability, efficacy, ability to combine with first line chemotherapy and then in randomised first line trials by the OCTIPS consortium. By translating the clinical observation of treatment failures into innovative cancer models that mimic relapsed ovarian cancer, we will validate improved front-line therapeutic strategies to help prolong patient survival. The impact of this application is that it defines a highly rigorous approach to integrate the bedside to bench to bedside paradigm, leading to novel prognosis-changing strategies for the treatment of ovarian cancer patients.'